Showing 1441-1450 of 1564 results for "".
- Horizon Therapeutics to Acquire Viela Bio to Grow Rare Disease Medicine Portfoliohttps://modernod.com/news/horizon-therapeutics-to-acquire-viela-bio-to-grow-rare-disease-medicine-portfolio/2478819/Horizon Therapeutics and Viela Bio announced the companies have entered into a definitive agreement under which Horizon will acquire all of the issued and outstanding shares of Viela Bio common stock for $53 per share in cash, which represents a fully diluted equity value of approximately $3.05 b
- J&J’s Single-Dose COVID-19 Vaccine 66% Effectivehttps://modernod.com/news/jjs-single-dose-covid-19-vaccine-66-effective/2478814/Johnson & Johnson reported topline results Friday showing that its investigational single-dose vaccine candidate Ad26.COV2.S met all primary and key secondary endpoints of the phase 3 ENSEMBLE study, with an overall efficacy rate of 66% at preventing moderate-to-severe COVID-19, 28 days after
- Pacific Vision Surgery Center Opens Doors to Bay Area Communityhttps://modernod.com/news/pacific-vision-surgery-center-opens-doors-to-bay-area-community/2478751/Pacific Vision Foundation has announced the opening of the new Pacific Vision Surgery Center. This state-of-the-art surgical facility is the manifestation of Pacific Vision Foundation’s mission to make excellent eye care available for all, regardless of ability to pay, while training the next gen
- Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-first-patients-enrolled-in-phase-1-2a-clinical-trial-of-cls-ax-for-the-treatment-of-wet-amd/2478744/Clearside Biomedical announced that the first patients have been enrolled in its phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). Clinical sites, all based in the United States, are activated and curr
- PolyActiva Completes Initial Clinical Trial With Latanoprost FA SR Ocular Implant for 6-Month Glaucoma Treatmenthttps://modernod.com/news/polyactiva-completes-initial-clinical-trial-with-latanoprost-fa-sr-ocular-implant-for-6-month-glaucoma-treatment/2478494/PolyActiva announced it has successfully completed its phase I clinical study for its lead candidate, the Latanoprost FA SR Ocular Implant. The device was well tolerated in all 8 patients with no significant safety findings. The study also showed that the implant persists for the entire 6-
- Tarsus Pharmaceuticals Announces Closing of Initial Public Offeringhttps://modernod.com/news/tarsus-pharmaceuticals-announces-closing-of-initial-public-offering/2478442/Tarsus Pharmaceuticals announced the closing of its initial public offering of 6,325,000 shares of its common stock at a price to the public of $16.00 per share, which includes 825,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock. All of
- Low Vision Resources and Rehabilitation for Retinal Degeneration Patients: A Webinar to Discuss Critical Needs and Opportunitieshttps://modernod.com/news/low-vision-resources-and-rehabilitation-for-retinal-degeneration-patients-a-webinar-to-discuss-critical-needs-and-opportunities/2478431/The Foundation Fighting Blindness is hosting a low vision webinar to inform eye care professionals about the many opportunities to greatly enhance the quality of life, and provide hope, for their retinal disease patients. The interactive webinar is appropriate for all eye care professional
- J&J Pauses COVID-19 Vaccine Studies After “Unexplained Illness”https://modernod.com/news/jj-pauses-covid-19-vaccine-studies-after-unexplained-illness/2478407/Johnson & Johnson confirmed that it paused further dosing in all clinical studies of its COVID-19 vaccine candidate JNJ-78436735, including the phase 3 ENSEMBLE trial, due to an “unexplained illness” in a participant. The company noted that the subject’s illness is being rev
- Biotech Healthcare Launches Optiflex TRIO Trifocal IOL in Europehttps://modernod.com/news/biotech-healthcare-launches-optiflex-trio-trifocal-iol/2478350/Switzerland-based Biotech Healthcare has announced the European launch of the Optiflex Trio, a diffractive-refractive trifocal toric IOL designed to treat presbyopia and with astigmatism. Its unique diffraction pattern gives a balanced light distribution at all three distances: near, intermediate
- Bausch Health Acquires Option To Purchase Ophthalmology Assets Of Allegro Ophthalmicshttps://modernod.com/news/bausch-health-to-acquire-option-to-purchase-all-ophthalmology-assets-of-allegro-ophthalmics/2478300/Bausch Health has entered into an agreement to acquire an option to purchase all ophthalmology assets of Allegro Ophthalmics, including global rights for risuteganib (Luminate)1, Allegro’s lead investigational compound in retina. Full financial terms of the deal were not d